Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 14/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531476 | 0.85 | CPS1 (0.54) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL30820833 | 0.85 | CPS1 (0.54) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL18506328 | 0.83 | CPS1 (0.53) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL28561525 | 0.81 | ALDH1A1 (0.49) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL1051747 | 0.81 | CPS1 (0.63) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL28102429 | 0.80 | CPS1 (0.57) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL15226106 | 0.79 | CPS1 (0.61) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL13362708 | 0.78 | HTT (0.44) | HPGDMEN1KMT2AALDH1A1GAA | |
| SCHEMBL29639738 | 0.77 | ALDH1A1 (0.65) | CPS1HPGDMEN1LMNAKMT2A | |
| SCHEMBL13830537 | 0.77 | ALDH1A1 (0.53) | HPGDMEN1LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-05-15 | — | — | US | disclosed |
| WO-2012085133-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | CYP2B6, CYP4B1, CIAPIN1 | CPS1 441/4885HPGD 76/4885MEN1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.